---
title: "輝瑞達成 105 億美元的腫瘤學交易，而禮來則在擴展其疫苗業務"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/288199750.md"
description: "輝瑞與信達生物達成了一項價值高達 105 億美元的協議，預付 6.5 億美元共同開發 12 個腫瘤學項目。同時，禮來正在收購 Curevo、LimmaTech 和 Vaccine Co.，總價值高達 40 億美元，以增強其疫苗組合。這些重大交易突顯了生物製藥領域跨境合作與競爭的加劇，可能加速全球對新治療方法的獲取"
datetime: "2026-06-01T02:05:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288199750.md)
  - [en](https://longbridge.com/en/news/288199750.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288199750.md)
---

# 輝瑞達成 105 億美元的腫瘤學交易，而禮來則在擴展其疫苗業務

Pfizer's cancer push: Pfizer will pay Innovent $650M upfront in a deal worth up to $10.5B, aiming to co-develop 12 oncology programs and expand its cancer drug pipeline. Lilly's vaccine spree: Eli Lilly will acquire Curevo, LimmaTech, and Vaccine Co. for up to $4B combined, bolstering its position in infectious disease prevention. Global market impact: These transactions signal heightened cross-border collaboration and competition in biopharma, potentially accelerating access to new treatments worldwide.

### 相關股票

- [PFE.US](https://longbridge.com/zh-HK/quote/PFE.US.md)
- [LLY.US](https://longbridge.com/zh-HK/quote/LLY.US.md)
- [01801.HK](https://longbridge.com/zh-HK/quote/01801.HK.md)
- [IBB.US](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [ELIL.US](https://longbridge.com/zh-HK/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/zh-HK/quote/LLYX.US.md)
- [XBI.US](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [IHE.US](https://longbridge.com/zh-HK/quote/IHE.US.md)
- [FBT.US](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/zh-HK/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [LABU.US](https://longbridge.com/zh-HK/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [ELIS.US](https://longbridge.com/zh-HK/quote/ELIS.US.md)
- [IBBQ.US](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [LABD.US](https://longbridge.com/zh-HK/quote/LABD.US.md)
- [IXJ.US](https://longbridge.com/zh-HK/quote/IXJ.US.md)
- [LLYZ.US](https://longbridge.com/zh-HK/quote/LLYZ.US.md)

## 相關資訊與研究

- [太空經濟第一個顛覆的行業，為什麼會是醫藥？](https://longbridge.com/zh-HK/news/289197942.md)
- [分析師稱瑞他魯肽數據鞏固禮來在肥胖症市場的優勢，股價應聲大漲](https://longbridge.com/zh-HK/news/289044514.md)
- [禮來公司強調女性在更年期各個階段的減重益處](https://longbridge.com/zh-HK/news/289069387.md)
- [AlzeCure 就阿爾茨海默病藥物與禮來簽署合作及對外授權協議](https://longbridge.com/zh-HK/news/289141264.md)
- [阿斯利康加入減肥藥賽道：口服藥減重 11.8%](https://longbridge.com/zh-HK/news/289144891.md)